Introduction:
AGC Biologics is planning to build a new manufacturing facility at AGC Inc.’s Yokohama Technical Center in Japan.
Features:
This expansion is part of AGC Biologics' strategic growth strategy to enhance pharmaceutical development and manufacturing services in the Asia region.
The new facility aims to address the global demand for biologics and advanced therapy medicinal products (ATMPs).
The facility will cater to a broad spectrum of services, encompassing pre-clinical to commercial stages, focusing on mammalian-based protein biologics, cell therapies, and messenger RNA (mRNA).
The facility will feature multiple 2,000 L single-use bioreactors and several 4,000 L or larger reactors for mammalian cell culture services.
Once completed, the Yokohama site will be one of Japan's largest for mammalian-based manufacturing capacity.
The new facility is anticipated to meet the needs of regional and global developers seeking biopharmaceutical development and manufacturing capabilities.
It is also expected to contribute significantly to maximizing operational and supply chain efficiencies across AGC Biologics' global network.
AGC Biologics plans for the Yokohama facility to be operational by 2026.
Specifications:
Name AGC Biologics
Type Construction
Year 2026
